---
id: idsa-candidiasis-2016
title: "IDSA Clinical Practice Guideline for the Management of Candidiasis"
short_title: "IDSA Candidiasis 2016"

organization: Infectious Diseases Society of America
collaborators: null
country: US
url: https://www.idsociety.org/practice-guideline/candidiasis/
doi: 10.1093/cid/civ933
pmid: 26679628
open_access: true

specialty: infectious-disease
guideline_type: clinical-practice
evidence_system: other
conditions:
  - candidiasis
  - candidemia
tags:
  - echinocandins
  - fluconazole
  - amphotericin B
  - step-down therapy

publication_date: 2016-01-01
previous_version_date: 2009-01-01
status: current
supersedes: idsa-candidiasis-2009
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-22
---

# IDSA Clinical Practice Guideline for the Management of Candidiasis

## Scope
Evidence-based recommendations for treatment of mucocutaneous and invasive candidiasis, including candidemia, in nonneutropenic and neutropenic patients.

## Key Recommendations

### Candidemia in Nonneutropenic Adults

#### First-Line Treatment (Strong, High)
- **Echinocandin** (preferred):
  - Caspofungin: 70 mg loading, then 50 mg daily
  - Micafungin: 100 mg daily
  - Anidulafungin: 200 mg loading, then 100 mg daily

#### Alternative
- **Fluconazole**: 800 mg (12 mg/kg) loading, then 400 mg (6 mg/kg) daily
- Use for less critically ill patients without recent azole exposure
- Not for C. glabrata or C. krusei

#### Transition to Oral
- If susceptible to fluconazole and clinically stable, transition to oral fluconazole
- After 5-7 days of IV therapy

#### Duration
- **14 days** after first negative blood culture AND resolution of signs/symptoms

#### Catheter Management
- **Remove central venous catheters** when possible
- Source control is essential component of treatment

### Candidemia in Neutropenic Adults

#### First-Line Treatment (Strong, High)
- **Echinocandin** (preferred)

#### Alternatives
- Lipid formulation amphotericin B: 3-5 mg/kg daily
- Fluconazole: If no prior azole exposure

#### Duration
- **14 days** after first negative blood culture, resolution of neutropenia, and resolution of signs/symptoms

### Chronic Disseminated Candidiasis (Hepatosplenic)
- **Initial**: Lipid formulation amphotericin B or echinocandin for several weeks
- **Step-down**: Fluconazole 400 mg daily
- **Duration**: Continue until lesions resolve (often months)

### Candida Endocarditis
- Lipid formulation amphotericin B ± flucytosine, OR
- High-dose echinocandin (caspofungin 150 mg, micafungin 150 mg, anidulafungin 200 mg)
- Valve replacement strongly recommended
- Long-term (lifelong) suppressive fluconazole if surgery not possible

### Central Nervous System Candidiasis
- Lipid formulation amphotericin B ± flucytosine
- Duration: Until CSF and clinical abnormalities resolved

### Oropharyngeal Candidiasis
- **First-line**: Fluconazole 100-200 mg daily for 7-14 days
- **Alternative**: Nystatin suspension, clotrimazole troches
- **Refractory**: Higher-dose fluconazole, itraconazole, or echinocandin

### Esophageal Candidiasis
- **First-line**: Fluconazole 200-400 mg (3-6 mg/kg) daily for 14-21 days
- Empiric therapy without endoscopy acceptable if typical symptoms
- **Refractory**: Itraconazole, posaconazole, echinocandin, or amphotericin B

### Vulvovaginal Candidiasis

#### Uncomplicated
- Topical azole (1-7 days) OR
- Fluconazole 150 mg single dose

#### Recurrent (≥4 episodes/year)
- Induction: Fluconazole 100-200 mg every 72 hours x 3 doses
- Maintenance: Fluconazole 100-200 mg weekly for 6 months

### Species-Specific Considerations
- **C. glabrata**: Higher echinocandin doses may be needed; avoid fluconazole
- **C. krusei**: Intrinsically resistant to fluconazole; use echinocandin or amphotericin B
- **C. auris**: Multi-drug resistant; echinocandin preferred (see updated guidance)
